Theravance Biopharma, Inc.

NASDAQ:TBPH

Biotechnology

Healthcare
$17.03 -0.42%

-$0.07 today

Market cap
$882.64M
Beta
0.18
P/E (TTM)
7.4
EPS (TTM)
$2.23
52W Low $10.44High $21.03

Volume 10.02M

Average 0.43M

TBPH Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Theravance Biopharma, Inc.NASDAQ: TBPH

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents rises 160.5% from a year ago

Cash & equivalents stood at $288.1M at the end of Q1 FY2026, up 160.5% from a year earlier and up 71.7% from the prior quarter. Over 3 fiscal years it compounded at -17.4% a year.

Context

  • Cash & equivalents amounted to 61.0% of total assets at the end of Q1 FY2026, up 28.8 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +160.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$288.1M+71.7% QoQ
Last fiscal yearDec 2025
$167.81M+344.0% YoY
Year agoMar 2025
$110.61M+160.5% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+160.5%——
1 year+344.0%——
3-year CAGR-17.4%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
167.81M USD
Year-over-year change
+344.0%
4-year CAGR
+16.9%

Cash & Equivalents vs competitors

How TBPH compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +160.5% is the highest of 9, against a peer median of -7.3%.
  • Cash & equivalents amounts to 61.0% of total assets for TBPH, versus a peer median of 21.2%.
TBPH Competitors
Cash & Equivalents for TBPH and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
TBPHTheravance Biopharma, Inc.Mar 2026$288.1M USD+160.5%-17.4%61.0%
VIRVir Biotechnology, Inc.Mar 2026$276.09M USD+0.9%-34.9%26.9%
GLUEMonte Rosa Therapeutics, Inc.Mar 2026$159.86M USD+103.6%+33.2%21.7%
REPLReplimune Group, Inc.Dec 2025$122.95M USD-28.6%+1.6%36.9%
VALNValneva SEMar 2026€105.37M EUR-31.1%-27.6%28.3%
TYRATyra Biosciences, Inc.Mar 2026$84.96M USD-15.7%-32.5%20.6%
GERNGeron CorporationMar 2026$70.78M USD-15.5%+11.8%13.3%
AVBPArriVent BioPharma, Inc. Common StockMar 2026$62.1M USD+24.5%-34.7%17.8%
LENZLENZ Therapeutics, Inc.Mar 2026$24.77M USD+7.5%-17.3%9.1%
Peer median (excluding TBPH) —-7.3%-22.4%21.2%

Competitors are the stored peer set for TBPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents89.96M298.17M39.55M37.8M167.81M
Short-term Investments83.51M29.31M62.88M50.55M147.55M
Net Receivables57.6M16.79M17.47M68.44M95.54M
Inventory00000
Other Current Assets8.56M7.68M11.6M4.2M7.56M
Total Current Assets249.87M353.46M133.54M161.07M418.46M
Property, Plant & Equipment (Net)53.35M52M45.36M35.77M30.27M
Goodwill00000
Intangible Assets00000
Long-term Investments68.37M00014.35M
Tax Assets00000
Other Non-current Assets3.23M201.94M203.1M157.32M22.5M
Total Non-current Assets124.95M253.94M248.46M193.09M67.11M
Total Assets374.82M607.4M382M354.16M485.57M
Account Payables3.1M1.55M1.52M2.24M2.57M
Short-term Debt17.44M00010.95M
Tax Payables0005.85M0
Deferred Revenue98K24K000
Other Current Liabilities25.15M(24K)12.88M06.91M
Total Current Liabilities58.59M28.72M24.77M32.09M38.3M
Long-term Debt599.39M00032.8M
Deferred Tax Liabilities240K00085.68M
Deferred Revenue (Non-current)310K192K000
Other Non-current Liabilities2.18M91.29M99M107.42M313K
Total Non-current Liabilities654.81M136.89M144.24M146.53M150.55M
Total Liabilities713.39M165.6M169M178.62M188.85M
Common Stock1K1K001K
Retained Earnings(1.73B)(853.91M)(909.1M)(965.52M)(859.63M)
Accumulated OCI(0)(15K)(65K)7K61K
Other Stockholders Equity00(0)(0)0
Minority Interest00000
Total Equity(338.57M)441.8M213M175.55M296.72M
Total Debt669.52M52.16M49.16M49.82M75.5M
Net Debt579.56M(246.01M)9.61M12.02M(92.31M)

Theravance Biopharma, Inc.

NASDAQ:TBPH

Intrinsic Alpha fair value

Locked

Current Price

$17.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.